JP-153

JP-153 is the Src-FAK-Paxillin signaling inhibitor. JP-153 inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) . JP-153 reduces VEGF-induced migration and proliferation in retinal endothelial cells. JP-153 can be uesd for the study of neovascular eye disease[1].

Product Specifications

CAS Number

[1802937-26-3]

UNSPSC

12352005

Target

FAK; Src

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.45

Solubility

DMSO : 200 mg/mL

Smiles

O=C1OC(C2=CC(OC)=C(OC)C(OC)=C2)C3=CC=C4C=CC=CC4=C3N1

Molecular Formula

C21H19NO5

Molecular Weight

365.38

References & Citations

[1]Toutounchian JJ, et al. Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis. Mol Pharmacol. 2017 Jan;91 (1) :1-13. doi: 10.1124/mol.116.105031. Epub 2016 Nov 9. Erratum in: Mol Pharmacol. 2017 Dec;92 (6) :627.